Sun Pharmaceutical Industries Limited reported earnings results for the third quarter and nine months ended December 31, 2025. For the third quarter, the company reported sales was INR 154,690.7 million compared to INR 134,369.4 million a year ago. Revenue was INR 160,993.8 million compared to INR 141,410.8 million a year ago. Net income was INR 33,688.1 million compared to INR 29,033.8 million a year ago. Basic earnings per share from continuing operations was INR 14 compared to INR 12.1 a year ago. Diluted earnings per share from continuing operations was INR 14 compared to INR 12.1 a year ago.
For the nine months, sales was INR 436,603.6 million compared to INR 392,256.7 million a year ago. Revenue was INR 453,634.7 million compared to INR 409,717.7 million a year ago. Net income was INR 87,653.9 million compared to INR 87,791.6 million a year ago. Basic earnings per share from continuing operations was INR 36.5 compared to INR 36.6 a year ago. Diluted earnings per share from continuing operations was INR 36.5 compared to INR 36.6 a year ago.
Sun Pharmaceutical Industries Ltd. is one of the Indian leaders of pharmaceutical groups. Net sales break down by family of products as follows:
- generic and OTC medicines (94%): for cardiologic, psychiatric, neurological, gastroenterological, diabetic and respiratory diseases treatment;
- other (6%) : primarily active pharmaceutical ingredients.
At the end of March 2021, the group had 44 production plants worldwide.
Net sales are distributed geographically as follows: India (33%), the United States (31.3%), other (35.7%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
